Search clinical trials for: Safety of an adjuvanted vaccine

Total 490082 results

Valneva Austria GmbH

Recruiting

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Zika | Zika Virus Infection

United States
Arcturus Therapeutics, Inc.
Novotech (Australia) Pty Limited; Seqirus

Not yet recruiting

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

COVID-19
National Institute of Allergy and Infectious Diseases...
Duke University; National Institutes of Health (NIH); Department of Health and... and other collaborators

Not yet recruiting

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

HIV

United States, South Africa
Central Adelaide Local Health Network Incorporated
National Health and Medical Research Council, Australia; University of Adelaide and other collaborators

Not yet recruiting

Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients (SIR ZOSTER)

Immunosuppression | Vaccine Response Impaired
ANRS, Emerging Infectious Diseases
LinKinVax; Vaccine Research Institute (VRI), France

Not yet recruiting

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

COVID-19
Arcturus Therapeutics, Inc.
Novotech (Australia) Pty Limited; Seqirus

Recruiting

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Influenza, Human

Australia
CanSino Biologics Inc.

Recruiting

A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years

Herpes Zoster

Canada
International AIDS Vaccine Initiative
3M; Polymun Scientific GmbH; Access to Advanced Health Institute (AAHI)

Not yet recruiting

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

Hiv

Netherlands
Seqirus
Department of Health and Human Services

Recruiting

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection Viral

Philippines, United States
International AIDS Vaccine Initiative
National Institute of Allergy and Infectious Diseases (NIAID); Access to Advanced...

Not yet recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate

Hiv
Fundacion Clinic per a la Recerca Biomédica
Polymun Scientific GmbH

Recruiting

Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults (HIVAC-FOUND)

Healthy

Spain
National Institute of Allergy and Infectious Diseases...

Recruiting

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Epstein-Barr Virus Infection | Infectious Mononucleosis | Herpesvirus

United States
GlaxoSmithKline
Biological E. Limited

Recruiting

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

Typhoid Fever

Belgium
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Hepatitis B

Germany, United Kingdom, Belgium
D'Or Institute for Research and Education
Bill and Melinda Gates Foundation; Instituto Fernandes Figueira

Not yet recruiting

Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19) (TP-SCB-2019001)

Covid19

Brazil
Seqirus
Biomedical Advanced Research and Development Authority

Active, not recruiting

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection Viral

United States
IrsiCaixa
José Moltó Marhuenda, PhD, MD; Beatriz Mothe Pujadas PhD,MD; Susana Benet Garrabé... and other collaborators

Completed

A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

HIV Infection

Spain
The University of Queensland
Syneos Health; Coalition for Epidemic Preparedness Innovations

Completed

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Covid19 | SARS-CoV2

Australia
Seqirus

Active, not recruiting

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Quadrivalent Influenza Vaccine Compared to a Non-adjuvanted Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age

Influenza, Human

Turkey, Belgium, Bulgaria, Czechia, Finland, Georgia, Italy, Korea, Republic of, Lithuania, Netherlands, Poland, Romania, Spain, Taiwan
Institut Pasteur
Wellcome Trust; Walter Reed Army Institute of Research (WRAIR); Parexel; Bill &... and other collaborators

Completed

A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a (GlycoShig3)

Healthy

Kenya
Seqirus

Completed

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Influenza | Human

United States
SK Bioscience Co., Ltd.
GlaxoSmithKline; International Vaccine Institute; Coalition for Epidemic Preparedness...

Completed

Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)

Covid19

Thailand, Korea, Republic of, New Zealand, Philippines, Ukraine, Vietnam
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Influenza, Human

United States
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Influenza

United States
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

Respiratory Syncytial Virus Infections

France, Finland, Belgium, Spain, United Kingdom
GlaxoSmithKline

Active, not recruiting

Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)

Infections, Soft Tissue

United States, South Africa, Australia, India, New Zealand, United Kingdom, Poland
GlaxoSmithKline

Active, not recruiting

Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Hepatitis B, Chronic

Taiwan, Belgium, Thailand, Germany, Spain, Hong Kong, United Kingdom, France, Poland
LiteVax BV
University Hospital, Ghent

Completed

Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin (TETRALITE-I)

Influenza

Belgium
International AIDS Vaccine Initiative
Massachusetts General Hospital; GlaxoSmithKline; Fred Hutchinson Cancer Research... and other collaborators

Completed

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

HIV Infections

United States, Kenya
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Active, not recruiting

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b Adjuvanted With 3M-052-AF + Alum in Healthy, HIV-1 Uninfected Adult Participants

HIV-1-infection

United States
National Institute of Allergy and Infectious Diseases...
Department of Health and Human Services; HIV Vaccine Trials Network; Inovio Pharmaceuticals and other collaborators

Active, not recruiting

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

HIV Infections

United States, South Africa
Serum Institute of India Pvt. Ltd.

Completed

Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine

Poliomyelitis

Bangladesh
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years

Clostridium Infections

Belgium
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants (HVTN 135)

HIV Infections

South Africa
Seqirus

Completed

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Influenza, Human

United States, Estonia, Germany
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Suspended

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

HIV

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

HIV-1-infection

United States
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP); Institut...

Completed

Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Malaria,Falciparum

Burkina Faso
SK Bioscience Co., Ltd.
GlaxoSmithKline; International Vaccine Institute; Coalition for Epidemic Preparedness...

Active, not recruiting

Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted With AS03 in Adults Aged 18 Years and Older

COVID-19

Colombia, Nepal
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Safety and Tolerability | Compare SHINGRIX Vaccine Response Rates

United States
Medicago

Completed

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

Influenza

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine (CHIKV VLP)

Chikungunya Virus

United States
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults

COVID-19

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

HIV Infections

United States
University of Melbourne
Southern Star Research Pty Ltd.

Completed

Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults

SARS-CoV-2

Australia
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Cervical Intraepithelial Neoplasia

United States
Novartis Vaccines

Completed

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

Seasonal Influenza

Italy
SK Bioscience Co., Ltd.
Coalition for Epidemic Preparedness Innovations

Completed

Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
SK Bioscience Co., Ltd.

Completed

Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area

Zika Virus Infection

Puerto Rico

3

Subscribe